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Abstract  
 
Vitamin D deficiency is associated with high risk of colon cancer and a variety of other 
diseases. The active vitamin D metabolite 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) 
regulates gene transcription via its nuclear receptor (VDR), and posttranscriptional 
regulatory mechanisms of gene expression have also been proposed. We have identified 
microRNA-22 (miR-22) and several other miRNA species as 1,25(OH)2D3 targets in 
human colon cancer cells. Remarkably, miR-22 is induced by 1,25(OH)2D3 in a time-, 
dose-, and VDR-dependent manner. In SW480-ADH and HCT116 cells, miR-22 loss-of-
function by transfection of a miR-22 inhibitor suppresses the antiproliferative effect of 
1,25(OH)2D3. Additionally, miR-22 inhibition increases cell migration per se and 
decreases the antimigratory effect of 1,25(OH)2D3 in both cell types. In silico analysis 
shows a significant overlap between genes suppressed by 1,25(OH)2D3 and miR-22 
putative target genes. Consistently, mi -22 inhibition abrogates the 1,25(OH)2D3–
mediated suppression of NELL2, OGN, HNRPH1, RERE and NFAT5 genes. In 39 out of 
50 (78%) human colon cancer patients, miR-22 expression was found lower in the 
tumour than in the matched normal tissue and correlated directly with that of VDR. 
Our results indicate that miR-22 is induced by 1,25(OH)2D3 in human colon cancer cells 
and it may contribute to its antitumour action against this neoplasia. 
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INTRODUCTION 
 
Vitamin D deficiency is increasingly associated with a variety of human diseases (1, 2). 
Among them, colorectal cancer is particularly important as many epidemiological studies link 
high risk of developing this neoplasia to low vitamin D diet or circulating level of calcidiol 
(25-hydroxyvitamin D3) (3, 4). In line with this, experimental data in cultured cells and 
animal models show that the most active vitamin D metabolite 1α,25-dihydroxyvitamin D3 
(1,25(OH)2D3) exerts potent protective effects against colon cancer (and other neoplasias) (5-
7).  
 1,25(OH)2D3 is a pleiotropic hormone that regulates many genes in numerous tissues 
in the organism. Its classical model of action implies the binding to, and activation of a 
member of the superfamily of nuclear receptors, the vitamin D receptor (VDR). VDR acts as a 
ligand-modulated transcription factor that binds to specific sequences (VDRE, vitamin D 
response elements) in target genes and increases or decreases their transcription rate through 
the interaction with a vast array of co-activators, co-repressors, and chromatin modifier 
enzymes and remodelling complexes (8, 9). Recent data, however, indicate that a number of 
1,25(OH)2D3 target genes are regulated by posttranscriptional and/or posttranslational 
mechanisms (10-12). 
 MicroRNAs (miRNAs) are short non-coding RNAs with wide gene regulatory activity 
at the posttranscriptional level. MiRNAs associate with several proteins in RNA silencing 
complexes that cause mRNA degradation or translation inhibition, or both processes (13). In 
recent years, miRNAs have been shown to play key roles in cancer as they control the 
expression of crucial oncogenes and tumour suppressor genes and, accordingly, several 
miRNAs are either over-expressed or silenced affecting tumour progression and metastasis 
(14, 15). 
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To gain insight into the action of 1,25(OH)2D3 in colon cancer, we have searched for 
novel targets by screening with miRNAs microarrays. Among the candidate targets identified, 
we focused on miR-22 based on previous data suggesting its tumour suppressor activity (16-
21). 1,25(OH)2D3 modulates cell proliferation: it usually has a mild to medium cell-type 
dependent inhibitory effect although stimulatory effects have also been reported (22, 23). Our 
results show that miR-22 is induced by 1,25(OH)2D3 and contributes to its inhibitory effects 
on the proliferation and migration of colon cancer cells. Moreover, we found that anti-miR-22 
expression abrogates the regulation by 1,25(OH)2D3 of the RNA levels of several target 
genes. Importantly, miR-22 is downregulated in a high proportion of colon tumours and its 
expression correlates directly with that of VDR. Together, these data show that miR-22 is a 
target of 1,25(OH)2D3 and mediates in part its protective action against colon cancer. 
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RESULTS 
 
miR-22 is induced by 1,25(OH)2D3 
To study whether 1,25(OH)2D3 affects miRNA expression in human colon cancer we 
profiled with miRNA microarrays RNA samples extracted from SW480-ADH cells that 
were treated for different time points either with 10-7 M 1,25(OH)2D3 or the corresponding 
amount of vehicle (control). A series of miRNA species were consistently found to be 
upregulated (i.e. miR-146a, miR-22, miR-222) or downregulated (i.e. miR-203) (Fig. 1). 
Data have been deposited in GEO databases (GSE34564). On the basis of its kinetics of 
induction and the literature reporting its tumour suppressive activity in several systems, 
miR-22 was chosen for an in-depth study. 
 Validation of microarray data was performed by quantitative RT-PCR. The level of 
miR-22 increased in a time- and dose-dependent manner following 1,25(OH)2D3 treatment 
of SW480-ADH cells (Fig. 2A-B). Moreover, miR-22 was also induced by this hormone in 
five others human colon cancer cell lines (LS174T, HT29, SW1417, DLD-1, HCT116), 
while no induction was found in SW480-R and SW620 cells that lack VDR expression (5) 
(Fig. 2C). 
 
miR-22 mediates the antiproliferative and antimigratory effects of 1,25(OH)2D3 
Next, we examined whether the induction of miR-22 could be relevant for the inhibitory 
effect of 1,25(OH)2D3 on cell proliferation and migration of colon cancer cells. To this end, 
we first transfected SW480-ADH and HCT116 cells with a miR-22 oligonucleotide inhibitor 
(anti-miR-22) or a non-silencing control (scrambled oligonucleotide, SCR) and analyzed their 
proliferation in the presence or absence of 1,25(OH)2D3. In both cell types, the decrease in the 
number of viable cells, resulting from the sum of effects on cell division and survival caused 
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by the hormone, was blunted by the addition of anti-miR-22 but not by that of SCR 
oligonucleotide (Fig. 3A-B). Notably, in the absence of 1,25(OH)2D3 anti-miR-22 treatment 
did not alter cell division (Fig. 3A-B) but, in contrast, led to an increased migratory capacity 
in transwells assays (2.13 ± 0.3-fold, P = 0.0002, for HCT116 cells; 1.75 ± 0.38-fold, P = 
0.007, for SW480-ADH cells) (Fig. 4A and B). In line with this, anti-miR-22 abolished the 
inhibition of cell migration caused by 1,25(OH)2D3 in both cell types (Fig.4A-B). In all 
experiments, blockade of miR-22 induction by 1,25(OH)2D3 using anti-miR-22 was analyzed 
by qRT-PCR (Supplementary Material, Fig. S1). 
 
miR-22 mediates the regulation of several 1,25(OH)2D3 target genes 
We wished to explore the putative role of miR-22 in the gene regulatory effect of 
1,25(OH)2D3. To this end, we first did a comparative in silico analysis by using TargetScan 
(24) for predicted miR-22 targets and data from our transcriptomic studies of 1,25(OH)2D3 
target genes ((25) and unpublished data). This study rendered that 9 out of 36 genes (25%) 
downregulated and 11 out of 93 genes (11.8%) upregulated by the hormone in SW480-ADH 
cells are putative miR-22 targets (2.11-fold enrichment down- versus up-regulation) (Fig. 5A 
and Supplementary Material, Table S1). The comparison of these data with the predicted 
targets of a randomly selected group of miRs (miR-200a, miR-142-3p, miR-142-5p, miR-
320a, miR-31, miR-365 and miR-34b; median of total targets of 655 and median overlap with 
1,25(OH)2D3 targets of only 3) revealed the statistical evidence that miR-22 targets are 
enriched in the 1,25(OH)2D3-treated array dataset relative to other miRs.  
 To validate this finding we analyzed the expression of a few selected genes 
downregulated by 1,25(OH)2D3, such as neural tissue-specific epidermal growth factor-like 
repeat domain-containing protein (NELL2), osteoglycin (OGN), heterogeneous nuclear 
ribonucleoprotein H1 (HNRPH1), nuclear factor of activated T cells 5 (NFAT5), caudal type 
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homeobox 2 (CDX2) and arginine-glutamic acid dipeptide (RE) repeats (RERE) in SW480-
ADH and HCT116 cells transfected with either anti-miR-22 or SCR oligonucleotides. 
Supporting a role of miR-22 mediating the downregulation of these genes by the hormone, in 
either or both cell lines the transfection of anti-miR-22 oligonucleotides but not of SCR 
abrogated such inhibitory effect, except in the case of CDX2 (Fig. 5B and C). We also studied 
CDH1, a gene transcriptionally upregulated by the hormone that mediates part of its effects in 
colon cancer cells (5, 26). As expected from this regulation, anti-miR-22 did not affect the 
induction by 1,25(OH)2D3, suggesting that CDH1 mRNA may not be indeed a target of miR-
22. 
 
Expression of miR-22 in human colon tumours 
Finally, we studied the expression of miR-22 in 50 matched normal and tumour samples from 
human colon cancer patients. In agreement with a tumour suppressive action, miR-22 
expression was found downregulated in 39 out of 50 (78%) tumours as compared to normal 
tissue (Fig. 6A). In line with previous studies (27-29), VDR expression was downregulated in 
36 out of 50 (72%) tumours versus normal tissues (Supplementary Material, Fig. S2). 
Notably, a significant direct correlation was found between the expression of miR-22 and 
VDR RNA (Spearman correlation coefficient, r = 0.315, P = 0.026) (Fig. 6B), which suggests 
that the VDR-mediated induction of miR-22 observed in cultured cells probably also takes 
place in human colon tissue. 
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DISCUSSION 
 
In this study, we identify miR-22 as a target of 1,25(OH)2D3 in human colon cancer cells that 
mediates in part its inhibitory effect on cell proliferation and migration. The finding that an 
anti-miR-22 reduces the antiproliferative effect of 1,25(OH)2D3 strongly supports that the 
induction of miR-22 contributes to, and is not a mere consequence of the growth inhibitory 
action of the hormone. Moreover, miR-22 is found to mediate the repression by 1,25(OH)2D3 
of several genes such as OGN, NELL2, HNRPH1, RERE and NFAT5 at the RNA level, which 
we have validated as targets of this hormone in human colon cancer cells. 
 Supporting the consistency of these findings, they have been described in two cell 
lines that harbour different sets of mutations that are crucial and represent most human colon 
tumours: while SW480-ADH cells harbour mutated APC, TP53, and K-RAS genes, HCT116 
cells express a wild-type APC but a mutated CTNNB1/β−catenin that is the alternative 
responsible mechanism for the aberrant activation of the Wnt canonical signalling pathway, a 
hallmark of this neoplasia. Both cell types contain a mutated K-RAS but they differ with 
respect to the major tumour suppressor TP53, which is normal in HCT116 but mutated in 
SW480-ADH cells. 
 Several reasons support a role of the regulation of miR-22 for 1,25(OH)2D3 action in 
this system. First, our data show that miR-22 mediates the antiproliferative and antimigratory 
action of the hormone. Second, because the repression by 1,25(OH)2D3 of certain genes that is 
in part dependent on miR-22 may contribute to its antitumoural action: thus, NELL2 is 
repressed by the antitumour agent genistein in pancreatic cancer Panc1 cells (30), is over-
expressed in Burkitt’s lymphoma cells, neuronal tumours, and benign prostatic hyperplasia 
(31-33), and contributes to the survival promoting effects of estradiol via the ERK signalling 
pathway (34). HNRPH1 encodes a splicing regulator that is overexpressed in colon cancer and 
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counteracts apoptosis induced by etoposide and fluoropyrimidine anticancer drugs (35-37). 
NFAT5 transcriptional activity is induced by integrin α6β4 and Src oncogene (38), and 
mediates carcinoma invasion through the induction of S100A4 (39), and possibly also 
melanoma invasion (40). RERE (or ATN1) encodes a nuclear receptor corepressor that is 
aberrantly expressed in neuroblastoma and appears to be involved also in acute myeloid 
leukemia (41). Very little relation exists between OGN and cancer; paradoxicaly, it has been 
proposed to decrease gelatinase activity of murine hepatocarcinoma cells (42).  
 The relevance of miR-22 regulation by 1,25(OH)2D3 is also supported by the tumour 
suppressive effects of this miRNA recently described in other systems. Thus, miR-22 
suppresses cell proliferation and tumourigenicity and is downregulated in hepatocellular 
carcinoma (16), represses c-Myc binding protein, MYCBP, a positive regulator of the strong 
oncogene c-MYC (17), and controls the EVI-1 oncogene in breast cancer cells (18). 
Additionally, miR-22 is induced by p53 and favours p53-dependent apoptosis by targeting 
CDKN1A/p21CIP-1 RNA (19), although our data show that the induction of miR-22 by 
1,25(OH)2D3 is independent of p53 as it takes place in cells with either wild-type or mutant 
TP53 gene. Also, miR-22 suppresses the activity of nuclear factor kappa B (ΝFκΒ), an 
important inducer of cell survival and inflammatory and tumourigenic cytokines (20). 
Remarkably, miR-22 may have an anti-angiogenic effect in colon cancer via the inhibition of 
hypoxia inducible factor (HIF)-1α expression (21). Lastly, it has recently been reported the 
additive induction of miR-22 by testosterone and 1,25(OH)2D3 in the prostate cancer LNCaP 
cell line (43). Altogether, these data suggest that miR-22 induction may play a role in the 
antitumoural action of 1,25(OH)2D3. 
 Data obtained from human biopsies show the correlation between the expression of 
VDR RNA and miR-22, suggesting that 1,25(OH)2D3 may also regulate miR-22 expression in 
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vivo. Likewise, the downregulation of miR-22 concomitant to VDR silencing in tumours 
agrees with its tumour suppressive effects in cultured colon cancer cells. 
 In summary, we have identified miR-22 as a novel target of 1,25(OH)2D3 that expand 
the range of its gene expression modulatory activity at the posttranscriptional level and may 
contribute to explain at least partially its protective action on this important neoplasia.
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MATERIALS AND METHODS 
 
Cells and cell culture 
Human colon cancer SW480-ADH, HCT116, HT29, LS174T, DLD-1, SW620, SW1417 and 
SW480-R cell lines were cultured in DMEM plus 10% foetal bovine serum (Invitrogen). All 
experiments using 1,25(OH)2D3 or isopropanol (vehicle) were performed in medium 
supplemented with charcoal-treated serum.  
 
Cell proliferation and migration assays 
To measure proliferation, cells (15 x 103) were seeded in 24-well plates and treated for up to 3 
days with 10-7 M of 1,25(OH)2D3 or vehicle. Living cells were counted after trypsinization 
using a TC10™ Automated Cell Counter (Bio-Rad). For migration assays, cells were 
transfected with antisense or control oligonucleotides and 12 h later they were trypsinized and 
counted. Equal numbers (15 x 104) were seeded on the upper surface of 8.0 µm pore 
Transwells® (Corning Incorporated). 1,25(OH)2D3 (10-7 M) or vehicle was added to the upper 
and lower media. After 24 h incubation, cells on the upper surface of the filter were removed 
by using a cotton swab and those attached to the lower surface of the filters were stained using 
Diff-Quick reagents (Dade Behring) and counted (10 fields/Transwell®). Experiments were 
performed in triplicate. Phase-contrast images were captured with a Leica DC300 digital 
camera mounted on an inverted Leitz Labovert FS Microscope. All images were processed 
using Adobe Photoshop CS4 software. 
 
miRNA microarray analysis 
Microarrays were produced in the Genomics Unit of the Spanish National Cancer Research 
Centre (CNIO), Spain. Briefly, NCode Multi-Species miRNA V2 probeset (Invitrogen, cat. # 
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MIRMPS2-01) was printed on Nexterion epoxy E slides (Schott) by following manufacturer’s 
recommendations. Probe sequences target all of the known mature miRNAs in the Sanger 
miRBase Sequence Database, Release 9.0. Cellular small RNA fractions were extracted with 
PureLink miRNA isolation kit (Invitrogen) and labelled with the 2-color LabelIT miRNA 
labelling system (Mirus). Extracts from cells treated with 1,25(OH)2D3 or vehicle at each time 
point were compared in dye swapped hybridizations. Hybridization conditions were as per 
Mirus’ kit recommendations and microarrays were read with an Agilent G2505B scanner. 
Two hybridization batches were performed on a first series of cells cultured for 24, 48 or 72 h 
(data not shown). A last batch, in which all the samples were dye swapped in technical 
replicates, employed new cultures from a time series of 24, 48, and 96 h. Changes between 
1,25(OH)2D3 and vehicle treatments were apparent and steady but small, and statistically non-
significant. Biological replication (two replicates for time points 24 and 48 h) was 
insufficient. Entities that showed no signs of differential expression, with absolute fold 
change less than 1.5, were discarded from consideration. Raw data from microarray images 
were quantified, background subtracted, and global Lowess normalized with Feature 
Extraction Software (Agilent). Visualization of miRNA expression data showing relatively 
high intensity signals was carried out by importing processed data in MultiExperiment Viewer 
v4.7 (44) and MS Excel. The expression dataset was filtered to include only those probe sets 
detecting miRNAs with mean expression values showing at least a change of ±0.5 (log2 scale) 
between each pair of samples under comparison. Validation was carried out by qRT-PCR 
analysing three independent sets of samples. 
 
Transfection and miR-22 silencing 
To silence miR-22, cells were transfected with 25 nM of miRIDIAN anti miR-22 (hairping 
inhibitor oligonucleotide) or with a Caenorhabditis elegans miRNA not found in humans 
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[miRIDIAN miRNA Hairpin Inhibitor Negative Control 1 (SCR)] (Dharmacon) using the 
jetPEI reagent (PolyPlus Transfection) following manufacturer’s guidelines. Experiments 
were performed up to 72 h after transfection and the level of miR-22 silencing was monitored 
by qRT-PCR. 
 
Quantitative RT-PCR 
Total RNA (including small RNAs) from cultured cell lines was extracted using the 
NucleoSpin® miRNA extraction kit (Macherey-Nagel). RNA from ~30 mg of tumour or 
normal tissue was extracted using RNeasy mini kit (Qiagen). Quantitative real-time PCR 
(qRT-PCR) analyses of miR-22 expression level were performed using the miRNA-specific 
TaqMan MicroRNA Assay Kit (Applied Biosystems). Briefly, 12.5 ng of total RNA were 
reversed transcribed using the corresponding RT Primer and the TaqMan MicroRNA Reverse 
transcription Kit (Applied Biosystems). PCR was performed on 1.33 ml of RT products by 
adding the TaqMan PCR primers and the iQ Supermix (Bio-Rad). RNU44 small RNA was 
used for normalization of input RNA/cDNA levels. VDR, NFAT5, NELL2, OGN, CDX2, 
CDH1, RERE, and HNRPH1 RNA levels were measured using the primers listed in 
Supplementary Material Table S2 and the Power SYBR® Green PCR Master Mix (Applied 
Biosystems). RNA expression values were normalized versus the housekeeping gene 
succinate dehydrogenase complex subunit A (SDHA). The reaction was performed in a 
CFX384 Real-Time PCR Detection System (Bio-Rad). 
 
Patients and tumour samples 
Normal and tumour tissue samples from 50 colon cancer patients were obtained immediately 
after surgery, immersed in RNA later (Applied Biosystems), snap-frozen in liquid nitrogen 
and stored at -80ºC until processing. Tumours were considered sporadic cases because no 
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clinical antecedents of Familial Adenomatous Polyposis (FAP) were reported and those with 
clinical criteria of hereditary non-polyposis colorectal cancer (HNPCC) (Amsterdam criteria) 
were excluded. Tumours were examined by two different pathologists to: (a) confirm 
adenocarcinoma diagnosis and presence of at least 75% of tumour tissue in the sample, (b) 
determine the histological level of the tumour, and (c) verify the absence of tumour cells in 
normal tissue. All patients gave written informed consent. The protocol was approved by the 
Research Ethics Board of the Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, 
Spain. 
 
 
Statistical analysis 
Results are expressed as mean ± SD unless otherwise specified. Statistical significance was 
assessed by one-way analysis of variance (ANOVA) test with Bonferroni post-test. 
Differences were considered significant when P < 0.05. The single asterisk indicates P < 
0.05, the double asterisk P < 0.01, and the triple asterisk P < 0.001. All statistical analyses 
were performed using the Prism software V5 (GraphPad software). As the tumour/normal 
tissue (T/N) ratios of VDR and miR-22 expression were not normally distributed 
(Kolmogorov-Smirnov test, Lilliefords correction), we normalized the data distribution by 
using log10 for statistical analysis. Correlations between RNA expression levels were 
analyzed using the Spearman correlation coefficient.  
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SUPPLEMENTARY MATERIAL 
Supplementary material is available at HMG online. 
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LEGENDS TO FIGURES 
 
Figure 1. Identification of miRNAs regulated by 1,25(OH)2D3 in SW480-ADH cells 
using microarrays. RNA populations isolated from cells that were incubated with 10-7 M 
1,25(OH)2D3 for 24, 48, or 96 h with repeated addition of hormone every 24 h were 
hybridized to the arrays as indicated in Methods. Heat map showing the list of miRNA 
species that were upregulated (red) or downregulated (green). 
 
Figure 2. Induction of miR-22 expression by 1,25(OH)2D3 in human colon cancer cells. 
(A) qRT-PCR analysis of miR-22 expression levels in SW480-ADH cells at different 
times after addition of 10-7 M 1,25(OH)2D3. RNU44 was used for normalization. Mean ± 
SD (n = 3). (B) Dose-curve induction of miR-22 by 1,25(OH)2D3 in SW480-ADH cells. 
(C) qRT-PCR analysis of miR-22 levels after treatment with 10-7 M 1,25(OH)2D3 for 48 
h in a panel of human colon cancer cell lines that express (left) or lack (right) VDR. miR-
22 levels are shown relative to (untreated) LS174T cells after normalization to RNU44.  
 
Figure 3. Ectopic expression of anti-miR-22 abrogates the antiproliferative effect of 
1,25(OH)2D3. Proliferation capacity of HCT116 (A) or SW480-ADH (B) cells 
transfected with anti-miR-22 or a control oligonucleotide (SCR) in the presence or 
absence of 10-7 M 1,25(OH)2D3. In each panel, a representative experiment out of four 
performed in triplicate is shown. 
 
Figure 4. Anti-miR-22 abrogates the antimigratory effects of 1,25(OH)2D3. Migratory 
capacity of HCT116 (A) or SW480-ADH (B) cells transfected with anti-miR-22 or a 
control oligonucleotide (SCR) in the presence or absence of 10-7 M 1,25(OH)2D3. Cells 
were seeded in triplicate on Transwell filters and 24 h later cells on the upper surface of 
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the filters were swept out and migratory cells that had attached to the lower surface of 
filters were counted. Quantification of data of three independent experiments is shown 
(left). Representative phase-contrast images of cells attached to the lower surface of the 
filters that were stained with Diff-Quick reagents (right). 
 
Figure 5. Expression of anti-miR-22 abolishes the downregulation of several genes by 
1,25(OH)2D3. (A) Venn diagram representing the overlap between miR-22 predicted 
targets (TargetScan) and 1,25(OH)2D3-modulated genes identified in microarrays 
analyses of SW480-ADH cells. qRT-PCR analysis of NELL2, OGN, HNRPH, RERE, 
CDX2, CDH1 and NFAT5 mRNA expression in HCT116 (B) or SW480-ADH (C) cells 
treated for 48 h with 10-7 M 1,25(OH)2D3 or vehicle. SDHA was used for normalization.  
 
Figure 6. miR-22 expression in human colon cancer patients. (A) miR-22 levels were 
analyzed by qRT-PCR in normal and tumour tissue samples of 50 colon carcinoma 
patients. Quantification was performed as described in Methods. (B) Scattergram 
showing the relation between miR-22 and VDR RNA levels in each patient. 
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LEGENDS TO SUPPLEMENTARY FIGURES 
 
 
 
 
Supplementary Figure S1. Blockade of miR-22 induction by 1,25(OH)2D3 using anti-miR-
22. Three representative qRT-PCR analysis of miR-22 levels in HCT116 (A) and SW480-
ADH (B) cells transfected with anti-miR-22 or control oligonucleotide (SCR) in the 
presence or absence of 10-7 M 1,25(OH)2D3 for the indicated times. 
 
 
 
Supplementary Figure S2. VDR expression in human colon cancer patients. Levels of VDR 
RNA were analyzed by qRT-PCR in paired normal and tumour tissue samples of 50 colon 
carcinoma patients. Quantification was performed as described in Methods. 
 
 
 
Supplementary Table S1. miR-22 predicted targets regulated by 1,25(OH)2D3. 
Analysis was performed as described in Methods. 
 
 
Supplementary Table S2. Sequence of primers for amplification of each gene by qRT-
PCR.  
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Supplementary Table S1 
 
 
Reference Symbol Fold Change Seed Match Position 3’UTR 
NM_014057 OGN -4.34 8mer 509-515 
NM_001113178 NFAT5 -3.71 7mer-m8 2264-2270 
NM_005520 HNRNPH1 -4.28 7mer-1A 22-28 
NM_006159 NELL2 -2.26 8mer 91-97 
NM_002847 PTPRN2 -1.68 7mer-m8 1262-1268 
NM_016205 PDGFC -1.65 7mer-m8 1174-1180 
NM_001265 CDX2 -1.58 8mer 498-505 
NM_003655 CBX4 -1.38 7mer-m8 267-273 
NM_001042681 RERE -1.44 7mer-1A 1724-1730 
 
 
Page 23 of 33 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 24
 
 
Supplementary Table S2. 
 
 
Gene Forward primer Reverse primer 
CDH1 AGAACGCATTGCCACATACACTC  CATTCTGATCGGTTACCGTGATC  
CDX2 TCTGGGCTGCTGCAAACGCT CCTGGTTTTCACTTGGCTGCCG 
HNRPH1 TCGCGTGTCTAGTTTGTTTCGACG CATCGGCCGAGCAAGACCAGG 
NFAT5 CGCGAGATTCTCTGAAGTTACACCC GGCAAATCCAGCAGCAACAACAGC 
NELL2 TGCCTTTACAACAGAGGGAGACGA GACGCACTCCGGTCGTGGAC 
OGN AATGATGAAATGCCCACGTGTCTGC GGCTGATTCCTTTGGTAAGGGTGGT 
RERE GGTGTAGCGCTTTAGGGGAAGCATT TCTCACGGCTAGGCCTCCGT 
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 
VDR TTGCCATACTGCTGGACGC GGCTCCCTCCACCATCATT 
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ABBREVIATIONS 
1,25(OH)2D3, 1α,25-dihydroxyvitamin D3; ERK, extracellular signal-regulated kinase, SCR, 
scrambled; VDR, vitamin D receptor; VDRE, vitamin D response element 
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